Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DNL 151

Next Previous
Drug Profile

DNL 151

Alternative Names: BIIB-122; DNL-151

Latest Information Update: 24 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Biogen; Denali Therapeutics Inc
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 07 Nov 2025 Denali Therapeutics completes enrolment in phase-II LUMA trial in Parkinson's disease in US, Austria, Canada, France, Germany, Netherlands, Poland, Spain, China, Italy, Israel, Japan, UK (PO) prior to November 2025 (NCT05348785)
  • 01 May 2025 Biogen completes the enrolment of its Phase-II clinical trials in Parkinson's disease in USA, Austria, Canada, China, France, Germany, Israel, Italy, Japan, Israel, Netherlands, Poland, Spain, United KIngdom (PO) (NCT05348785)
  • 05 Dec 2024 Denali Therapeutics holds the Investigational New Drug application for phase IIa BEACON trial, before December 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top